SpringerProtocols: Abstract: Assay for Isolation of Inhibitors of Her2-Kinase Expression

10. Assay for Isolation of Inhibitors of Her2-Kinase Expression

By: Gabriela Chiosis¹, Adam B. Keeton²

Abstract

Full Text

Download PDF (269K)

Her2 (ErbB2) protein is overexpressed in breast and other solid tumors, and its expression is associated with progressive disease. Current therapies directed toward Her2 either block dimerization of the receptor or inhibit tyrosine kinase activity to disrupt intracellular signaling. However, little is known about alternative mechanisms for suppressing Her2 expression, possibly by inducing degradation or blocking synthesis. Here, we describe a hybrid western-blotting and enzyme-linked immunosorbent assay (ELISA) designed to identify in low- to medium-throughput format noncytotoxic compounds that reduce expression of Her2 protein.

Affiliation(s): (1) Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
(2) Southern Research Molecular Libraries Screening Center, Assay Implementation Group, Southern Research Institute, Birmingham, AL, USA

Book Title: Cell-Based Assays for High-Throughput Screening: Methods and Protocols

Series: Methods in Molecular Biology | Volume: 486 | Year: 2009 | Page Range: 139-149 | DOI: 10.1007/978-1-60327-545-3_10

Subject: Biochemistry

Key Words: Breast cancer - Heat-shock protein 90 (Hsp90) - Her2 (ErbB2) tyrosine kinase - Whole-cell immunoblot

References

Download References

1.	Yarden, Y. and Sliwkowski, M. X. (2001) Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2, 127–137.

2.	Klapper, L. N., Kirschbaum, M. H., Sela, M., and Yarden, Y. (2000) Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77, 25–79.

3.	Yu, D. and Hung, M. C. (2000) Over-expression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19, 6115–6121.

4.	Ross, J. S. and Gray, G. S. (2003) Targeted therapy for cancer: the HER-2/neu and Herceptin story. Clin. Leadersh. Manag. Rev. 17, 333–340.

5.	Arteaga, C. (2003) Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin. Oncol. 3 Suppl 7, 3–14.

6.	Citri, A., Gan, J., Mosesson, Y., Vereb, G., Szollosi, J., and Yarden, Y. (2004) Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep. 12, 1165–1170.

7.	Citri, A., Kochupurakkal, B. S., and Yarden, Y. (2004) The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 1, 51–60.

8.	Aoyagi, S. and Archer, T. K. (2005) Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends. Cell Biol. 11, 565–567.

9.	Huezo, H., Vilenchik, M., Rosen, N., and Chiosis, G. (2003) Microtiter cell-based assay for the detection of agents that alter cellular levels of Her2 and EGFR. Chem. Biol. 10, 629–634.

10.	Llauger, L., He, H., Kim, J., Aguirre, J., Rosen, N., Peters, U., Davies, P., and Chiosis, G. (2005) 8-Arylsulfanyl and 8-arylsulfoxyl adenine derivatives as inhibitors of the heat shock protein 90. J. Med. Chem. 48, 2892–2905.

11.	He, H., Zatorska, D., Kim, J., Aguirre, J., Llauger, L., She, Y., Wu, N., Immormino, R. M., Gewirth, D. T., and Chiosis, G. (2006) Identification of potent water-soluble purine-scaffold inhibitors of the heat shock protein 90. J. Med. Chem. 49, 381–390.

12.	Stockwell, B. R., Haggarty, S. J., and Schreiber, S. L. (1999) High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. Chem. Biol. 2, 71–83.

13.	Mayer, T. U., Kapoor, T. M., Haggarty, S. J., King, R. W., Schreiber, S. L., and Mitchison, T. J. (1999) Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286, 971–974.

14.	Haggarty, S. J., Mayer, T. U., Miyamoto, D. T., Fathi, R., King, R. W., Mitchison, T. J., and Schreiber, S. L. (2000) Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis. Chem. Biol. 4, 275–286.

15.	Blaskovich, M. A., Sun, J., Cantor, A., Turkson, J., Jove, R., and Sebti, S. M. (2003) Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 63, 1270–1279.

16.	Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., and Schreiber, S. L. (2003) Domain-selective small molecule inhibitor of HDAC6-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA 100, 4389–4394.

17.	Haggarty, S. J., Koeller, K. M., Kau, T. R., Silver, P. A., Roberge, M., and Schreiber, S. L. (2003) Small molecule modulation of the human chromatid decatenation checkpoint. Chem. Biol. 12, 1267–1279

Comments (Loading...)

Post comment/View all comments